Incyte stock hit 11% despite paediatric dermatology trials hitting target
The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.
The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.
What's Your Reaction?
